AstraZeneca's U.S. trial data a confidence booster for COVID-19 shot
blank

By Josephine Mason, Ben Blanchard and Ludwig Burger LONDON/TAIPEI (Reuters) – AstraZeneca’s COVID-19 vaccine performed better than expected in a major late-stage trial, paving the way for its potential emergency authorization in the United States and boosting confidence in the shot after setbacks in Europe. The drugmaker said on Monday that interim data from trials in Chile, Peru and the United States found the vaccine was 79% effective in preventing symptomatic COVID-19 and, crucially, posed no increased risk of blood clots. AstraZeneca intends to request U.S. emergency authorization for the …

Read More

HEDGE accordingly